AVEO Pharmaceuticals, Inc. Expected to Post Q1 2019 Earnings of ($0.05) Per Share (AVEO)
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) – Equities researchers at B. Riley issued their Q1 2019 earnings estimates for shares of AVEO Pharmaceuticals in a report issued on Tuesday. B. Riley analyst M. Kumar anticipates that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter. B. Riley has a “Buy” rating and a $5.00 price objective on the stock. B. Riley also issued estimates for AVEO Pharmaceuticals’ Q2 2019 earnings at ($0.05) EPS, Q3 2019 earnings at ($0.04) EPS, Q4 2019 earnings at ($0.04) EPS, FY2020 earnings at $0.02 EPS and FY2022 earnings at $0.23 EPS.
A number of other equities analysts have also weighed in on the stock. BidaskClub lowered shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 27th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, assumed coverage on shares of AVEO Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $4.05.
Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in AVEO Pharmaceuticals by 48.6% during the 2nd quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the last quarter. Emory University purchased a new stake in AVEO Pharmaceuticals during the 4th quarter valued at $1,682,000. Essex Investment Management Co. LLC raised its stake in AVEO Pharmaceuticals by 34.1% during the 4th quarter. Essex Investment Management Co. LLC now owns 202,004 shares of the biopharmaceutical company’s stock valued at $564,000 after buying an additional 51,384 shares during the last quarter. X Square Capital LLC purchased a new stake in AVEO Pharmaceuticals during the 4th quarter valued at $557,000. Finally, Prosight Management LP purchased a new stake in AVEO Pharmaceuticals during the 4th quarter valued at $2,951,000. Institutional investors and hedge funds own 51.82% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “AVEO Pharmaceuticals, Inc. Expected to Post Q1 2019 Earnings of ($0.05) Per Share (AVEO)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/14/aveo-pharmaceuticals-inc-expected-to-post-q1-2019-earnings-of-0-05-per-share-aveo.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.